Urolog. pro Praxi, 2004; 5: 206-209

Tadalafil - moderní možnost v léčbě erektilní dysfunkce

MUDr. Libor Zámečník, prof. MUDr. Jan Dvořáček DrSc
Urologická klinika 1. LF UK a VFN Praha

Keywords: tadalafil, erectile dysfunction, PDE-5 inhibitor.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zámečník L, Dvořáček J. Tadalafil - moderní možnost v léčbě erektilní dysfunkce. Urol. praxi. 2004;5(5):206-209.

Sexuální aktivita je velmi důležitou součástí spokojeného a plnohodnotného partnerského života. Bezproblémová erekce je nevyhnutelnou podmínkou k uspokojivému pohlavnímu životu muže a její poruchy jsou jedny z nejčastějších příčin sexuálních problémů páru. V moderní léčbě erektilní dysfunkce je s úspěchem užíváno několik perorálních preparátů. Článek shrnuje dosavadní zkušenosti jak lékařů, tak pacientů s dlouhodobě účinkujícím tadalafilem.

TADALAFIL - A MODERN OPTION IN THE TREATMENT OF ERECTILE DYSFUNCTION

Sexual activity is a very important part of satisfactory and valuable partner life. The erection as good as gold is an inevitable condition to satisfactory sexual life of man, but erectile dysfunctions are one of the most frequent reasons of sexual problem in a couple. Modern therapy of erectile dysfunction uses successfully several oral drugs. Article summarises existing experiences of both doctors and patients with long-acting tadalafil.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Brock GB, Mc Mahon CG, Chen KK, et al. Efficacy and safety of tadalafil in the treatment of erectile dysfunction: results of integrated analyse. J. Urol., 2002; 168: 1332-1336. Go to original source... Go to PubMed...
    2. De Tejada IS, Anglin G, Knight JR, et al. Effects of Tadalafil on Erectile Dysfunction in Men With Diabetes. Diabetes Care, 2002; 25: 2159-2164. Go to original source... Go to PubMed...
    3. Eardley I, Ahuja S, Denne J, et al. Time distribution of sexual intercourse attempts after taking Tadalafil or placebo. Int. J. Import. Res., 2003; 15 (suppl 6): 21.
    4. Emmick JT, Stuewe SR, Mitchell M. Overview of the cardiovascular effects of tadalafil. Eur. Heart Jour. Supplem. 2002; 4 (suppl. H): H32-H47. Go to original source...
    5. Govier F, Potempa AJ, Kaufman J, et al. A Multicenter, Randomized, Double-blind, Crossover Study of Patient Preference for Tadalafil 20 mg or Sildenafil Citrate 50 mg Dutiny Initiation of Fragment for Erectile Dysfunction. Clinical Therapeutics, 2003; 25: 2709-2723. Go to original source... Go to PubMed...
    6. Hellstrom WJG, Overstreet JM, Yu A, et al. Tadalfil has no detrimental effecdt on human sparmatogenesis or reproductive hormones. J. Urol., 2003; 170: 887-891. Go to original source... Go to PubMed...
    7. Kubíček V. Tadalafil - nový blokátor PDE-5 pro léčbu erektilní dysfunkce z hlediska praktického urologa. Urologie pro praxi, 2003; 4: 49-53.
    8. Montorsi F, Ahuja S, Brock G, et al. Tadalafil in the teatment of ED following bilateral nerve-sparing radical retropubic prostatectomy. Int. J. Import. Res., 2003; 15 (suppl 6): 4.
    9. Padma-Nathan H, Rosen R, Shabsigh R, et al. Tadalafil (IC351) provides prompt response and extended period of responsiveness for the treatment of men with erectile dysfunction (ED). Int. J.Impot. Res., 2001; 13 (suppl. 4): 33. Go to original source... Go to PubMed...
    10. Patterson B, Bedding A, Jewell H, et al. Dose-normalized pharmacokinetic properties of tadalafil (IC351). Int. J. Import. Res., 2001; 13 (suppl. 5): 63.
    11. Patterson B, Bedding A, Jewell H, et al. The effect of intrinsic and extrinsic factors on the phmarmacokinetic properties of tadalafil (IC351). Int. J. Import. Res., 2001; 13 (suppl. 4): 43.
    12. Porst H, Arnds S, Kleingarn M. A comparator trial between Sildenafil, Tadalafil and Vardenafil - Preliminary results in 150 patients. Int. J. Import. Res., 2003; 15 (suppl 6): 5.
    13. Porst H, Arnds S, Kleingarn M. What patients prefer and why - Sildenafil vs. Tadalafil in a real life at home setting. Int. J. Import. Res., 2003; 15 (suppl 6): 21.
    14. Porst H, Rosen, RC, Padma-Nathan H, et al. Tadalafil allows men with erecdtile dysfnction to have successful intercourse up to 36 hours postdose. J. Urol., 2002; 167 (suppl. 4): 177. Go to PubMed...
    15. Ströberga P, Murphy A, Costigan T, et al. Switching Patiens with Erectile Dysfunction from Sildenafil Citrate to Tadalafil: Results of a European Multicenter, Open Label Study of Patient Preference. Clinical Therapeutics, 2003; 25: 2724-2737. Go to original source... Go to PubMed...
    16. Von Keitz A, Rajfer J, Segal S, et al. A Multicenter, Randomized, Double-Blind, Crossover Study to Evaluate Patient Preference between Tadalafil and Sildenafil. Eur. Urol., 2004; 45: 499-509. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.